In order to provide sustained hemostasis or tissue sealing, fibrin sealants must generate adhesive clots with mechanical properties capable of resisting forces, such as shear, that might break or tear the clot. Commercial preparations of fibrin sealants should generate clots of adequate and consistent mechanical strength. The mechanical strength of fibrin sealants is often measured as bonding strength in in vivo or ex vivo animal wound models. These tests can be useful predictors of clinical efficacy. However, these, as well as many in vitro tensile strength tests for fibrin sealant, tend to be laboratory specific and require extensive reagent preparation time and analyst training. The thromboelastograph has historically been used to screen for plasma protein and platelet disorders that lead to defective clot formation. The authors have developed a simple in vitro test, using a standard thromboelastograph that can provide reliable, reproducible information on the rheology of clots generated by fibrin sealant preparations. Using this method, the shear strength of fibrin sealant clots was measured and shown to correlate with the fibrinogen, but not the thrombin, concentration in the sealant. Shear strength was also shown to correlate with the sealant concentration of the fibrin crosslinking proenzyme, factor XIII. Sealants containing lysine, which can act as an alternate substrate for factor XIII enzyme and prevent efficient fibrin chain cross-linking, were shown by this method to generate clots of substantially reduced shear strength. The method distinguished between thrombincatalyzed clot formation and other fibrinogen clotting mechanisms as evidenced by the significantly lower shear strength associated with batroxobin-generated fibrin clots. Key Words: Fibrin sealant&mdash;Rheology&mdash;Thromboelastograph&mdash;Coagulation.
Summary: In order to provide sustained hemostasis or tissue sealing, fibrin sealants must generate adhesive clots with mechanical properties capable of resisting forces, such as shear, that might break or tear the clot. Commercial preparations of fibrin sealants should generate clots of adequate and consistent mechanical strength. The mechanical strength of fibrin sealants is often measured as bonding strength in in vivo or ex vivo animal wound models. These tests can be useful predictors of clinical efficacy. However, these, as well as many in vitro tensile strength tests for fibrin sealant, tend to be laboratory specific and require extensive reagent preparation time and analyst training. The thromboelastograph has historically been used to screen for plasma protein and platelet disorders that lead to defective clot formation. The authors have developed a simple in vitro test, using a standard thromboelastograph that can provide reliable, reproducible information on the rheology of clots generated by fibrin sealant preparations. Using this method, the shear strength of fibrin sealant clots was measured and shown to correlate with the fibrinogen, but not the thrombin, concentration in the sealant. Shear strength was also shown to correlate with the sealant concentration of the fibrin crosslinking proenzyme, factor XIII. Sealants containing lysine, which can act as an alternate substrate for factor XIII enzyme and prevent efficient fibrin chain cross-linking, were shown by this method to generate clots of substantially reduced shear strength. The method distinguished between thrombincatalyzed clot formation and other fibrinogen clotting mechanisms as evidenced by the significantly lower shear strength associated with batroxobin-generated fibrin clots. Key Words: Fibrin sealant&mdash;Rheology&mdash;Thromboelastograph&mdash;Coagulation.
During blood coagulation, multiple biochemical reactions occur which ultimately result in the generation of an active enzyme, thrombin, from an inactive precursor protein, prothrombin (factor II). Thrombin cleaves the fibrinogen molecule to yield fibrin molecules, which polymerize to form a soluble fibrin clot. Another plasma protein, factor XIII, is required in its active form to enzymatically cross-link the fibrin strands and form a highly stable clot. Calcium ions are required for the function of both thrombin and activated factor XIII. In the vasculature, platelets and blood cells can become enmeshed in the clot to form a hemostatic plug (1) . Fibrin sealants or fibrin glues are products that comprise separate preparations of thrombin and of fibrinogen/factor XIII and which, when mixed at a site of injury, generate a clot similar to the natural hemostatic plug (2) . The rate of clot formation upon mixing is controlled by the concentration of the thrombin component in the fibrin sealant ; different clotting rates may be more or less beneficial for specific indications. When sustained hemostasis is desired, the concentrations of fibrinogen and factor XIII appear to be important in determining the strength and elasticity of the fibrin sealant clot. The strength and adhesive properties of the fibrin sealant-generated clot can be presumed to be important, especially when the fibrin sealant is used to control high-pressure (arterial) and low-pressure (venous) bleeding.
The breaking (tensile) strength and shear strength of clots formed by fibrin sealants have been measured in multiple test systems (3) (4) (5) (6) (7) (8) . Most of these test systems have been surface-bonding tests patterned after the American Society for Testing and Materials (ASTM) standards for adhesives (9) (10) (11) . Typically, two identical biological surfaces, such as animal cadaver skin flaps (3) , cartilage, or bone (4), are attached to moveable fixtures and glued together with fibrin sealant. The moveable fixtures are then pulled apart until the fibrin sealant clot ruptures and the breaking force is measured by means of load cells. In other systems (5, 6) , incisional skin wounds have been inflicted on animals and the wounds closed by application of fibrin sealant. After a period of healing, the area around the wound is excised and skin on opposite sides is attached to moveable fixtures. The moveable fixtures are then pulled apart until the clot breaks and the breaking force is measured. Alternately, a formed clot can be prepared with fibrin sealant components in a mold, removed from the mold, and attached at opposite ends to moveable fixtures (7, 8) . The moveable fixtures are then pulled apart until the clot breaks and the breaking force is measured. These tests provide little information on the kinetics or rheology of sealant clot formation, both of which may be clinically important. Many of the tests require the lethal use of animals or specialized surgical procedures for the preparation of tissue specimens, making the tests ethically or technically difficult to perform. In addition, because of the variability often observed in animal systems and in the surgical skills of technicians, these tests may not provide the precision needed to quantitate sealant clot strength.
We have evaluated the ability of thromboelastography (TEG) to characterize the shear elastic modulus strength of clots formed by fibrin sealant. TEG was originally developed in 1948 by Hartert (12) . In a clinical setting, TEG has been used to monitor clot formation and fibrinolysis following the ex vivo or in vitro activation of patient whole blood or plasma. It is capable of identifying a multitude of coagulopathies and is useful in monitoring the viscoelastic properties of whole blood during the perioperative period (13) . TEG is particularly sensitive to platelet and fibrinogen levels in whole blood but
has not yet been used in a routine manner to characterize clots formed by purified fibrinogen and thrombin in the absence of platelets and other blood components. We report here the use of TEG to identify the concentrations of components in fibrin sealant preparations that are necessary for function.
MATERIALS AND METHODS

Materials
Batroxobin was purchased from Pentapharm (Basel, Switzerland). Fresh-frozen plasma was purchased from Pacific Hemostasis (Huntersville, NC). L-Lysine was purchased from Sigma Chemical Co. (St. Louis, MO).
Preparation of fibrin sealant components
The human thrombin component of fibrin sealant was prepared at Alpha Therapeutic Corporation (ATC) (Los Angeles, CA) by chromatography of cryoprecipitatepoor plasma on a DEAE ion exchange resin to generate prothrombin complex concentrate (PCC), activation of the PCC, and purification of the resultant thrombin by chromatography. The thrombin component of fibrin sealant was formulated to contain 40 mM calcium to support thrombin activity. Viruses were inactivated and removed from the thrombin component by incubation with solvent detergent (14) and nanofiltration of the product through a membrane with a mean pore size of 15 nm (15) . The thrombin component was formulated as a lyophilized powder in vials. Following reconstitution of the powder with the recommended amount of sterile water (5 mL), the concentration of thrombin was about 400 U/mL. The fibrinogen component of fibrin sealant was prepared at ATC from cryoprecipitate-poor plasma by standard manufacturing techniques including alcohol and salt precipitation. The fibrinogen component was formulated as a lyophilized powder in vials. Viruses were inactivated or removed from the fibrinogen component by incubation with solvent detergent during manufacture and extensive heating of the lyophilized product. Following reconstitution of the powder with the recommended amount of sterile water (5 mL), the concentration of fibrinogen was about 70 mg/mL. Only source plasma that tested negative for the presence of infectious agents such as human immunodeficiency virus (HIV 1 and 2) and hepatitis B and C viruses (HBV, HCV) by immunological or polymerase chain reaction (PCR) techniques was used in the manufacture of fibrin sealant components.
Coagulation assays
Thrombin was measured in a clotting assay in which sample was incubated with 8 mg/mL of purified fibrinogen (ATC). Clot formation was detected in a Coag-A-Mate X-2 coagulometer (Organon Teknica; Durham, NC). Thrombin concentration was calculated by comparing the sample clot time to the clot times obtained for a standard thrombin preparation that was reference assayed to the National Institutes of Health Standard. Fibrinogen was measured by determination of total clottable protein as described by Gaffney and Wong (16) . Factor XIII in fibrinogen was measured as described in the European Pharmacopoeia (17) with the following modifications. The sample was serially diluted in 0.9% saline containing 0.4% albumin and the dilutions were incubated in test tubes with calcium, thrombin, and 2 mg/mL of bovine fibrinogen free from factor XIII activity (Enzyme Research Laboratories; South Bend, IN) for I hour at 37°C until clot formation occurred. The clots were dissolved by periodic shaking in a solution of 6 M urea, 1 M sodium hydroxide, and 0.1 mg/mL phenolphthalein and dissolution times were noted. Factor XIII concentration was calculated by comparing the clot dissolution times for sample dilutions to the clot dissolution times obtained for dilutions of a referenced human plasma standard (Dade Behring Inc.; Newark, DE).
Thromboelastograph assay
The use of the TEG to measure the shear elastic modulus strength (SEMS) of plasma samples has been described (18, 19) . In this study, a Thromboelastograph Coagulation Analyzer, model 3000C (Haemoscope Corp.; Skokie, IL), was used to determine the SEMS of fibrin sealant under various conditions. The TEG instrument consisted of a temperature-controlled chamber (37°C) that contained two work stations. Each work station contained a cup, which was rotated back and forth slowly through an angle of 4 degrees, 45 minutes and a pin, which was suspended freely within the cup from a torsion wire. The instrument was calibrated prior to use. Fibrinogen solution (180 VLL) was added to each cup followed by 180 ~LL of thrombin solution. When necessary, the thrombin component was diluted with histidinebuffered saline containing calcium (HBSC) buffer and the fibrinogen component was diluted with tris(hydroxymethyl)aminomethane/citrate-buffered saline (TCBS) buffer prior to assay. The combined fibrin sealant solution was mixed by rapid insertion and retraction of the pin three times in the rotating cup. After mixing the sample, the pin was left in the lowered position and the event marker was depressed to mark the start of data collection. A layer of mineral oil was applied to the surface of the clot to prevent dehydration during the test cycle. When the clot started to form across the space between the cup and the pin, the motion of the cup and the pin were coupled and the rotational movement of the pin was converted by an electromagnetic transducer to an electrical signal that was monitored and recorded by computer. The computer recorded and plotted pin movement in both the clockwise and counterclockwise directions simultaneously as separate curves. The lag time from the start of data collection to clot formation and a pin movement greater than 2 mm was considered to be the reaction time (R) needed to initiate fibrin formation. The period of time during which pin motion increased from zero to the maximum was considered to be due to clot strengthening and adherence of the clot to the pin and walls of the cup. The distance between the two curves in millimeters was the amplitude (A) of the tracing and has been correlated with the ability of the clot to perform mechanical work throughout its structural development (12) . The point at which the tracing reached its maximum amplitude (MA) was considered to be the point at which the clot reached a maximum rigidity.
The TEG was calibrated such that an amplitude of 50 mm on the plot of signal versus time was equivalent to a SEMS of 5000 dyne/cm2. This represented 50% of the possible full-range deflection of 100 mm. The absolute SEMS of samples was calculated according to the following equation as described by Chandler (18):
where G is the SEMS in dyne/cm2. The kinetics of clot development was expressed as the K time, which was the time from the beginning of significant clot formation (R) until a fixed level of clot strength (amplitude = 20 mm) was reached. Testing was performed in duplicate on two separate dilutions of each sample and the mean of the four results was reported.
Statistics
For some experiments, linear regression was performed using the least-squares method and correlation coefficients (r) were determined. Means and standard deviations were determined by standard statistical procedures.
RESULTS
Effect of component concentrations on SEMS
When undiluted fibrin sealant components were tested, neither the R time nor the SEMS could be measured because clot formation was immediate and the MA exceeded 100 mm, equivalent to an infinite shear modulus. However, when fibrin sealant components were diluted prior to mixing, values for R and MA could be obtained. Following the introduction of fibrin sealant components (diluted 1:5) into the cup of the TEG, clot formation occurred, the clot adhered to the walls of the moving cup and the pin, and the motion of the cup and the pin were coupled. The increased motion of the pin FIG. 1. Fibrin sealant clot formation monitored by TEG. A, One vial of the lyophilized thrombin component of sealant and one vial of the lyophilized fibrinogen component were each reconstituted with 5 mL of sterile water as recommended by the manufacturer. An aliquot from the thrombin solution was diluted with 4 volumes of HBSC buffer and an aliquot from the fibrinogen solution was diluted with 4 volumes of TCBS buffer. One hundred-eighty microliters from each diluted aliquot were mixed in the TEG instrument and clot formation was monitored as described in the Materials and Methods section. B, Pooled fresh-frozen plasma was thawed and 270 pL of plasma was mixed with 80 pL of a 0.025 M CaC'2 solution in the TEG instrument and clot formation was monitored. was monitored by an electromagnetic transducer and is depicted graphically in Figure 1 A. An initial lag time (R value) of 9 seconds was observed in which pin movement was less than 2 mm and no observable clot formation occurred. Subsequently, there was a period in which there was increasing pin movement and noticeable fibrin formation. The MA for the TEG plot of clot formation was reached 61 1 minutes after the diluted sealant components were combined. The SEMS was calculated from the MA and Equation I to be 15,000 dyne/cm2. For comparison, Figure 1 B shows the TEG plot of clot formation for recalcified human plasma. The R value was 7 min for plasma clot formation and the MA was reached 19 minutes after recalcification.
The SEMS was calculated to be 1800 dyne/cM2. Figure 2 shows the effect that performing a series of equivalent dilutions on each component prior to mixing had on the TEG result. Quantifiable data were obtained only after a 5-fold dilution of both components (to 20% of the original concentrations). Further dilution of both components showed that the SEMS was proportional to dilutions of up to 20-fold (i.e., to 5% of the original concentration).
The role of individual component concentrations in contributing to the SEMS of the clot was also examined. The TEG assay was performed on samples in which the original thrombin component concentration was diluted from 5to 400-fold while the fibrinogen component concentration was held constant at 20% of the original concentration. As shown in Table 1 , the SEMS for all thrombin dilutions remained constant for clots formed with thrombin concentrations ranging from 20% to 0.25% of TABLE 1. Effect of thrombin concentration on shear elastic modulus strength and TEG K time
The lyophilized fibrinogen and thrombin components were reconstituted with 5 mL of sterile water and the fibrinogen component was diluted 5-fold with TCBS buffer. The thrombin component was diluted with HBSC as described in the text and combined in the TEG instrument with diluted fibrinogen. The MA and K time were determined and the SEMS was calculated as described in the Materials and Methods section. the original concentration (1-80 thrombin units/mL), suggesting that thrombin concentration did not affect clot strength. The differences in clot strength that were observed following dilution of both sealant components were therefore likely due to changes in fibrinogen concentration. Thrombin concentration did, however, affect the kinetics of clot development as evidenced by K times. K times ranged from 0.9 minute for thrombin component diluted 5-fold, to 5.1 minutes for thrombin component diluted 400-fold. The K times could be correlated with log thrombin concentration throughout this range (r = 0.9).
Calcium was required in the assay to promote thrombin-catalyzed fibrin formation. When the thrombin component was diluted with buffer that contained 40 mM of components were reconstituted with 5 mL of sterile water as recommended by the manufacturer and diluted with either TCBS buffer (fibrinogen) or HBSC buffer (thrombin). Identical dilutions of the fibrinogen and thrombin components were combined in the TEG instrument and the MA and SEMS were determined for each dilution as described in the Materials and Methods section. the chelator, ethylenediaminetetraacetic acid (EDTA), and no calcium, there was no evidence of clot formation, even after 2.5 hours of monitoring (results not shown). TEG assay specificity The ability of the TEG assay to distinguish between thrombin-generated clot formation and other fibrinogen clotting mechanisms was tested. Thrombin was replaced with a material known to produce a different type of fibrin clot from fibrinogen, the snake venom enzyme batroxobin. Fibrin clots formed with batroxobin are not as heavily cross-linked as clots formed with thrombin. The TEG assay was performed by combining the fibrinogen component of fibrin sealant (diluted 1:5) with either the thrombin component (also diluted I :5) or batroxobin, prepared as described in the Materials and Methods section. The results from both assays are summarized in Table 2 . The mean SEMS for clots formed by thrombincatalyzed fibrin formation was more than three times the value resulting from batroxobin-catalyzed clot formation.
Influence of product composition on SEMS
The fibrinogen component of fibrin sealant contained fibrinogen and significant levels of the proenzyme required for fibrin cross-linking, factor XIII. During the preparation of fibrin sealant used in this study, the fibrinogen was virally inactivated by extensive heating of the freeze-dried component. The effect of heating on fibrinogen function, factor XIII activity, and the SEMS of clots formed with heat-treated fibrinogen was evaluated. Lyophilized fibrinogen was heated for varying periods of time at 100°C as shown in Figure 3 . The heated fibrinogen component was reconstituted and fibrinogen and factor XIII concentrations were determined. Each heated fibrinogen preparation was then diluted, combined with a similarly diluted thrombin preparation, and the SEMS of the resultant clot was determined. As shown in Figure 3 , after 12 hours of heating, only a small loss (9%) of clottable fibrinogen was observed. How- ever, over the same 12-hour period, the factor XIII activity associated with the fibrinogen preparations decreased by 60%. Similarly, the strength of clots formed from fibrinogen heated for 12 hours decreased by 50%. This suggested that clot shear strength was strongly correlated with the amount of factor XIII in the fibrinogen component of fibrin sealant.
The effect of excipient composition on fibrin sealant function was evaluated. Table 3 shows the effect that inclusion of 3% lysine in the fibrinogen component had on shear strength. When multiple preparations of fibrinogen were evaluated by TEG, those preparations that contained 3% lysine produced clots with a shear strength that was 36% (±4%) less than the shear strength of clots formed from fibrinogen preparations that did not contain lysine. There was no difference in fibrinogen content for the preparations with and without lysine. The difference in SEMS in preparations containing lysine was evident even when other components in the preparation were changed (compare results for Formulation A and Formulation B). The decrease in shear strength suggests that cross-linking of fibrin was impaired in clots formed in the presence of lysine, perhaps by the inhibition of activated factor XIII activity.
DISCUSSION
Fibrin sealants, consisting of concentrated fibrinogen and thrombin solutions, have been used as therapeutic adhesives, wound sealants, and hemostats for decades (2) . Several companies manufacture sealant products and hospitals routinely prepare autologous fibrin sealant for their patients. The composition of these products can be widely variable in terms of purity and concentration. It is therefore important that quality control tests be established that can rapidly assess the suitability of fibrin sealant preparations for clinical use. While standardized methods for testing the function of individual sealant components are available, there is no generally accepted method for testing the functionality of the mixed product. To be effective, clots formed by sealant components after mixing must possess sufficient strength to resist shear and rupture stress during healing. The strength of clots formed with fibrin sealants can be measured mechanically. Thromboelastography was evaluated in this study and found to be a simple, rapid, and reproducible method for characterizing the mechanical strength of clots formed by different fibrin glue preparations.
The TEG assay can provide kinetic data on the rheology of fibrin clot formation that is not available from other in vitro test systems. The TEG provides a real-time determination of the onset of clot formation, the rate of clot formation, maximum clot strength, and degradation of the clot by proteolytic enzymes that may be present in a fibrin glue preparation. Other test systems that are designed to measure clot tensile (breaking) strength require FIG. 3 . The effect of dry heat treatment on fibrinogen activity, factor XIII activity, and clot shear strength. The fibrinogen component of fibrin sealant was prepared as described in the Materials and Methods section and lyophilized. The lyophilized fibrinogen was heated in an oven at 100°C. At varying time intervals, the heated fibrinogen was removed from the oven, reconstituted with 5 mL of sterile water, and the fibrinogen and factor XIII levels were determined for each heated preparation as described in the Materials and Methods section. Each of the heated and reconstituted fibrinogen preparations was diluted 5-fold with TCBS buffer and 180 pL was combined in a TEG instrument with 180 pL of thrombin component which had been diluted 5-fold with HBSC buffer. The MA was determined and the SEMS was calculated for each heated preparation as described in the Materials and Methods section.
the fibrin clot to be cast in a mold prior to attachment to moveable fixtures in a tensiometer (7, 8) . No information can be obtained in these systems about the kinetics or end point of clot formation. The length of time required to generate maximum clot strength will vary depending upon the fibrin sealant component composition. If the clot is placed in the tensiometer prematurely (before factor XIII-catalyzed cross-linking is complete), tensile strength can be underestimated. If clot formation is al- The fibrinogen component of fibrin glue was prepared as described in Materials and Methods. Lysine was added to some preparations prior to freeze-drying in an amount that would produce a final lysine concentration of 3% (w/v) when the fibrinogen component was reconstituted with the recommended 5 mL of sterile water. Fibrinogen and thrombin components were reconstituted and diluted 5-fold with TCBS (fibrinogen) or HBSC (thrombin) buffer prior to combining in the TEG instrument and determining SEMS as described in Materials and Methods. Formulations A and B differed from each other in the concentrations of major formulation excipients other than lysine. Two preparations, manufactured with and without lysine, were studied for each formulation. lowed to proceed for too long a period before tensiometry, the clot can dry out and harden or fracture during the measurement, leading to an over-or underestimate of tensile strength. In contrast, the TEG assay is performed in a closed system with constant monitoring of clot formation to ensure that data related to the peak of clot strength are always captured.
The TEG instrument was found to be unable to measure the shear elastic modulus strength of clots formed from undiluted fibrin sealant components. Clot formation occurred too quickly and clot strength was beyond the calibrated range of the instrument. In order to overcome this limitation, the sealant components needed to be diluted prior to assay. Both components were equally diluted with their respective formulation buffers (vehicle) before mixing. The SEMS of the clots that were formed decreased in proportion to the dilution over a dilution range of 1:5 through 1:20. Because of the strong correlation between dilution and clot strength and the fact that both components were maintained in product buffer throughout the dilution range, it was possible to estimate the SEMS of the undiluted fibrin sealant preparations by extrapolation. The estimated SEMS of undiluted fibrin sealant preparations approached 100,000 dyne/cm2. This value is much lower than tensile strength and breaking strength values ranging from 35 kPa (350,000 dyne/cM2) (20) to 1.11 x 105 N/cM2 (1, 110 ,000 dyne/cM2) (7) that have been reported for some fibrin sealant preparations. The lower SEMS values are not unexpected because the TEG is designed to measure the ability of fibrin clots to resist forces that are physiologically relevant rather than catastrophic. Although breaking strengths are not measured in the TEG assay, it might be logical to conclude that sealant preparations with high SEMS would have correspondingly high breaking strengths.
Clinical studies have demonstrated that platelet function, fibrinogen levels, and the activity of factors VIII and XIII contribute to clot strength as measured by TEG (13, 21) . Kaibara (22) and Carr et al. (23) have reported that the shear elastic modulus is proportional to the fibrinogen concentration in clots formed from plasma and pure solutions. Our results showed that decreasing the concentration of fibrinogen in fibrin sealants results in decreased SEMS. We also found that the estimated SEMS for undiluted sealant clots was about 35 times greater than the SEMS for clots formed by recalcified platelet-poor plasma, which is consistent with the relative difference in fibrinogen concentration between plasma and sealant preparations. We investigated the role that thrombin plays in clot formation and stabilization by diluting only the thrombin component of sealant preparations prior to TEG assay. Results showed that changes in thrombin concentration affect the rate of clot formation, but not clot strength. ' . The SEMS appears to be sensitive not only to fibrinogen concentration, but also to changes in fibrin sealant composition that affect the amount of cross-linking that takes place between fibrin strands in the clot. This study showed that during heating of the freeze-dried fibrinogen sealant component, the ability of the fibrinogen to form a clot is not impaired, even after 12 hours of heating. However, the strength of clots formed from the heated fibrinogen decreases by 50%. Since the major factor responsible for imparting structural stability to the clot is the transglutaminase activity of activated factor XIII, factor XIII-specific assays were performed on the heated fibrinogen. The factor XIII activity associated with the heated fibrinogen preparations was found to have decreased by 60%, suggesting that the decrease in shear strength was directly related to a decrease in the amount of factor XIII-catalyzed cross-linking that could be generated by a sealant preparation.
The responsiveness of the TEG assay to differences in fibrin cross-linking that might affect clot stability was further confirmed by studies with the snake venom enzyme, batroxobin. Batroxobin-catalyzed clot formation proceeds differently than thrombin-catalyzed clot formation. Thrombin cleavages occur in the aminoterminal regions of the Aa and BI3 chains and allow the fibrin molecules to stack on top of each other with adjacent fibrin D domains. Activated factor XIII then cross-links gamma chains through lysine and glutamine residues in adjacent D domains as well as through the same residues in the carboxytermini of adjacent alpha chains. This results in a large, cross-linked, three-dimensional structure.
Batroxobin, however, cleaves only the aminoterminal region of the alpha chains and generates a clot that can be stabilized only by cross-links between gamma chains (24) . The increased cross-linking in the thrombincatalyzed fibrin clots would be expected to produce stronger clots than those generated with batroxobin. The TEG assay was able to quantitate this difference, showing that clots formed with thrombin had shear strengths three times greater than the corresponding clots formed with batroxobin. These results also demonstrated the ability of the TEG assay to distinguish between thrombin-generated clot formation and other fibrinogen clotting mechanisms.
Excipients such as sugars, polyhydric alcohols, and amino acids are often added to fibrin glue preparations to stabilize the individual components. Results from this study demonstrate the utility of the TEG assay in assessing the effect of formulation excipients on the proper functioning of fibrin sealants. Preparations of the fibrinogen component that included the amino acid lysine generated clots with a much lower SEMS than fibrinogen preparations that did not include the amino acid. Presumably, this decreased resistance to shear was due to lysine acting as an alternate substrate for activated factor XIII in the transglutaminase reaction, preventing lysine residues in the fibrin strands from linking with opposing glutamine residues, thereby decreasing the overall amount of cross-linking in the clot. With this information, the development of products with formulations that might impair sealant function can be avoided.
Fibrin sealants have been clinically effective in many areas including the repair of ventricular septal defects (25) and aneurysms (26) , closure of tracheosophageal (27) , bronchopleural (28) and bladder (29) fistulae, elimination of bronchial and alveolar leakage after pulmonary resections (30) , control of bleeding during the repair of liver lacerations (31 ), reduction of postoperative cerebral spinal fluid leakage (32) , control of bleeding in hemophiliacs during tooth extraction (33) , fixation of skin grafts in burn patients (34) , and reducing the need for sutures during face-lift surgery (35) . Animal models are available which support the efficacy of fibrin sealants when used for these and other clinical indications (2, (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) . However, it is both impractical and unethical to use these animal systems to routinely evaluate the performance of the combined components in every manufactured batch of fibrin sealant. It would be preferred to have a test system that measures a property of the sealant that can be correlated to clinical efficacy either directly or through animal models. The value of the TEG assay is that it is simple, quantitative, and able to be validated.
Future studies with the TEG assay will correlate SEMS with animal and clinical data to establish the minimum shear strength necessary for clinical efficacy.
